HIMX vs NVDA

HIMX exhibits a strong operational health profile with a Piotroski F-Score of 7/9, yet this is overshadowed by severe fundamental deterioration. The stock is significantly overvalued relative to its Graham Number ($5.47) and Intrinsic Value ($1.82), while trading at a high P/E of 35.42 despite crashing YoY earnings (-74.20%) and revenue (-14.40%). Most critically, the dividend is unsustainable with a payout ratio of 142.31%, indicating the company is returning more capital than it generates.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.